CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 134 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q4 2017. The put-call ratio across all filers is 1.00 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $12,000 | -14.3% | 5,000 | 0.0% | 0.00% | – |
| Q4 2017 | $14,000 | -92.0% | 5,000 | -89.8% | 0.00% | – |
| Q1 2017 | $176,000 | -5.4% | 48,835 | 0.0% | 0.00% | – |
| Q4 2016 | $186,000 | +6100.0% | 48,835 | +6411.3% | 0.00% | – |
| Q3 2016 | $3,000 | -98.4% | 750 | -98.3% | 0.00% | – |
| Q2 2016 | $188,000 | +4600.0% | 42,885 | +4083.9% | 0.00% | – |
| Q1 2016 | $4,000 | -76.5% | 1,025 | -7.1% | 0.00% | – |
| Q4 2015 | $17,000 | +54.5% | 1,103 | +7.6% | 0.00% | – |
| Q3 2015 | $11,000 | -99.1% | 1,025 | -98.0% | 0.00% | -100.0% |
| Q2 2015 | $1,287,000 | +197.2% | 51,042 | +228.9% | 0.00% | +100.0% |
| Q1 2015 | $433,000 | -0.7% | 15,519 | -35.0% | 0.00% | – |
| Q4 2014 | $436,000 | +41.1% | 23,869 | +0.3% | 0.00% | – |
| Q3 2014 | $309,000 | -43.6% | 23,800 | -29.1% | 0.00% | -100.0% |
| Q2 2014 | $548,000 | – | 33,570 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TSP Capital Management Group, LLC | 813,273 | $3,286,000 | 1.66% |
| RTW INVESTMENTS, LP | 1,243,164 | $5,022,000 | 1.52% |
| Marcus Capital, LLC | 112,200 | $453,000 | 0.44% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 996,178 | $4,024,000 | 0.29% |
| Benchmark Capital Advisors | 67,000 | $271,000 | 0.20% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 360,299 | $1,456,000 | 0.20% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 2,907,523 | $11,746,000 | 0.15% |
| Virtus ETF Advisers LLC | 59,537 | $241,000 | 0.12% |
| Bellevue Group AG | 160,000 | $646,000 | 0.12% |
| PDT Partners, LLC | 428,300 | $1,730,000 | 0.10% |